Sat.May 13, 2023 - Fri.May 19, 2023

article thumbnail

Why Patients Are Demanding a More Digital Healthcare Payment Process

MedCity News

Patient demand for digital payment communication — both reminders about bills, as well as text messages that enable bill payment — is on the rise, according to a recent report. This is in line with growing consumerism trends in the U.S. — patients want their healthcare payment experience to mimic the convenience and ease they have when they pay for things like travel or retail goods.

article thumbnail

How AI Will Change the Way Patients Get Medication

MedCity News

There is a huge opportunity for PBMs and health systems to use AI to help address the challenges surrounding the affordability and accessibility of medicines, from navigating formularies to resolving prior authorization. More automation in pharmacies and with ordering workflows is one piece of that puzzle.

Medical 139
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Wyden blasts Big Pharma for tax ploys and lack of cooperation in probe

Fierce Pharma

Wyden blasts Big Pharma for tax ploys and lack of cooperation in probe kdunleavy Tue, 05/16/2023 - 10:51

Pharma 279
article thumbnail

US FDA approves Bausch + Lomb and Novaliq’s DED treatment Miebo

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval to Bausch + Lomb and Novaliq’s Miebo (perfluorohexyloctane ophthalmic solution) to treat the signs and symptoms of dry eye disease (DED). Formerly known as NOV03, Miebo is a first-in-class eye drop designed for preventing the evaporation of excessive tears and restoring tear balance in evaporative DED patients.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Building trust through transparency: Our pledge to provide more clarity around Web of Science journal coverage

Clarivate

As part of our on-going commitment to research integrity, we recently shared that we planned to investigate how we can provide greater transparency regarding which journals are covered in the Web of Science Core Collection. We thank our many community partners for their feedback and acknowledge the request for even more clarity around which journals are added or removed.

article thumbnail

How a Rural Health System Is Looking at Virtual Care and Remote Patient Monitoring

MedCity News

In a wide-ranging interview, Sanford Health’s president of virtual care explained how virtual care may be well suited to rural populations.

Patients 130

More Trending

article thumbnail

Could FDA recommend new antibiotic for hospital-acquired pneumonia?

European Pharmaceutical Review

A Phase III trial has found that the novel combination antibiotic sulbactam-durlobactam prevents at least as many fatalities of hospital-acquired pneumonia as colistin, the best currently approved treatment. This finding alongside the other data from the trial led the US Food and Drug Administration (FDA)’s Antimicrobial Drugs Advisory Committee to recommend the FDA approve the combination antibiotic for often-fatal pneumonia strain carbapenem-resistant Acinetobacter baumannii–calcoaceticus co

article thumbnail

Treatment options for Crohn’s disease expand after Rinvoq approval

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. Whilst there is a range of FDA-approved biologics for Crohn’s disease, Rinvoq is the first approved oral product for the moderate to severe type of the disease.

article thumbnail

Included Health, DispatchHealth Partner To Combine Virtual Care With Home Care

MedCity News

Included Health and DispatchHealth are partnering to combine Included’s virtual care services with DispatchHealth’s home care services. If an Included physician notices a patient requires in-person support, the physician will send DispatchHealth to the patient’s home.

article thumbnail

Intercept's NASH dreams may be dashed after FDA panel votes against Ocaliva's approval bid

Fierce Pharma

Intercept's NASH dreams may be dashed after FDA panel votes against Ocaliva's approval bid fkansteiner Fri, 05/19/2023 - 17:30

FDA 336
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

First NICE-recommended treatment for chronic heart failure

European Pharmaceutical Review

Final draft guidance has been published for the first National Institute for Health and Care Excellence (NICE)-recommended treatment for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. The regulatory body’s decision means up to 150,000 patients would be eligible for AstraZeneca-made dapagliflozin (Forxiga).

Medicine 105
article thumbnail

The 2023 PM360 ELITE 100

PM360

Maya Angelou said, “If you’re going to live, leave a legacy. Make a mark on the world that can’t be erased.” For nine years, we have looked to recognize those people in healthcare and life sciences who are making a mark on our industry, on patients, on colleagues, on the world. These people represent our ELITE 100: the individuals and teams who throughout their careers are building legacies marked by helping people live better—and hopefully longer—lives.

Education 105
article thumbnail

Meet the Startup Promising to Deliver the 1st Healthcare-focused Generative AI Model

MedCity News

Hippocratic AI emerged from stealth, as well as announced $50 million in seed funding through a round co-led by General Catalyst and Andreessen Horowitz. The Palo Alto-based startup bills itself as the first large language model designed specifically for healthcare.

article thumbnail

Bausch + Lomb bags FDA approval for dry eye disease treatment Miebo

Fierce Pharma

Bausch + Lomb bags FDA approval for dry eye disease treatment Miebo zbecker Fri, 05/19/2023 - 09:39

FDA 334
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Debiopharm commences pivotal glioblastoma therapy study

PharmaTimes

The therapy is a brain-penetrant used in various combinations in patients with progressive glioblastoma

Patients 105
article thumbnail

Recent developments in stem cell therapies

European Pharmaceutical Review

So far, 2023 has seen several major developments in stem cell-based therapies. Stem cells have the ability to self-renew. Their potential to differentiate into cells of different tissues makes them particularly interesting for applications in regenerative medicine. 1 Since the first therapy using stem cells was developed in 1957, only few stem cell-based therapies have entered the clinic 1 as advanced therapy medicinal products (ATMPs).

article thumbnail

Retail Clinics Are Gaining Momentum As They Vie for Their Piece of the Primary Care Pie

MedCity News

Retail clinic claims volumes have shot up by 200% in the past five years, according to a new report. The research argued that retailers are beginning to seriously compete with the traditional healthcare system when it comes to the primary care market — growth in retail clinic claims have greatly outpaced claims growth for urgent care centers, emergency departments and physician practices.

Retail 127
article thumbnail

Regulatory tracker: Another China-made PD-1 starts FDA journey as Elevar, Hengrui target big cancer type

Fierce Pharma

Regulatory tracker: Another China-made PD-1 starts FDA journey as Elevar, Hengrui target big cancer type aliu Wed, 05/17/2023 - 09:41

FDA 332
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

AstraZeneca’s dapagliflozin recommended by NICE

PharmaTimes

Treatment concerns up to 150,000 patients in England with chronic heart failure

Patients 104
article thumbnail

RWE shows efficacy of nirsevimab for infant RSV

European Pharmaceutical Review

Infants under 12 months who received a single dose of monoclonal antibody (mAb) nirsevimab showed an 83.21 percent reduction in hospitalisations due to respiratory syncytial virus (RSV) -related lower respiratory tract disease (LRTD), according to new real-world data from a Phase IIIb trial. Results from the Hospitalized RSV Monoclonal Antibody Prevention (HARMONIE) study were presented at 41st Annual Meeting of the European Society for Paediatric Infectious Diseases.

Safety 104
article thumbnail

Shifting to a More Holistic Approach Through 1115 Waivers

MedCity News

1115 waivers offer states a way to test new approaches in Medicaid that differ from what is required by federal statute. As we look at states leveraging Section 1115 Eligibility Changes, take notice of a strong emphasis on the justice-involved, housing/homelessness, and behavioral health.

125
125
article thumbnail

Pfizer, Seagen kick off antitrust review of $43B merger. Will FTC get on board?

Fierce Pharma

Pfizer, Seagen kick off antitrust review of $43B merger. Will FTC get on board?

328
328
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

NICE green light for Genedrive’s CYP2C19 candidate

PharmaTimes

Screening patients to assess their clopidogrel resistance status will allow for alternative treatments

Patients 100
article thumbnail

EMA issues guidance amidst European medicine shortage

Pharmaceutical Technology

The European Medicines Agency (EMA) has published recommendations to increase communication and planning efforts in a bid stop the current medicine shortages becoming even worse. Within the 14-page document , published by an EMA special task force, are 10 recommendations of best practices that “marketing authorisation holders, wholesalers, distributors, and manufacturers can consider adopting to ensure continuity of medicinal product supply and reduce the impact of shortages”.

article thumbnail

Emerging Investigators Are Pivotal for Meeting Current, Future Drug Development Needs

MedCity News

We must engage, train and support more physicians as investigators to enable the opportunity for their patients to have access to clinical trials. As an industry, we should be adding anywhere from 10% to 20% new investigators every year to meet the patient access needs for clinical trials.

article thumbnail

AbbVie, Genmab's lymphoma drug Epkinly snags FDA approval in heated blood cancer race

Fierce Pharma

AbbVie, Genmab's lymphoma drug Epkinly snags FDA approval in heated blood cancer race aliu Fri, 05/19/2023 - 11:21

FDA 321
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

PRH, PEN America Fight “Unconstitutional” School Book Bans

Copyright Clearance Center

The post PRH, PEN America Fight “Unconstitutional” School Book Bans appeared first on Copyright Clearance Center.

98
article thumbnail

Myeloid raises funds to support lead cell therapy programme

Pharmaceutical Technology

Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma. Led by Hatteras Investment Partners, the financing round has seen participation from existing investors, including 8VC, Alexandria Venture Investments and Newpath Partners, along with new investors Moore Strategic Ventures and ARCH Venture Partners.

Leads 98
article thumbnail

AbbVie’s Rinvoq Lands FDA Approval as First Oral Drug for Crohn’s Disease

MedCity News

FDA approval of blockbuster AbbVie drug Rinvoq makes it the first oral therapy for moderately to severely active Crohn’s disease. The regulatory nod is the seventh for the drug, which belongs to a class of therapies called JAK inhibitors.

FDA 119
article thumbnail

SCOTUS hands win to Sanofi, Regeneron in long-running PCSK9 feud with Amgen

Fierce Pharma

SCOTUS hands win to Sanofi, Regeneron in long-running PCSK9 feud with Amgen fkansteiner Thu, 05/18/2023 - 15:17

318
318
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time